Edwards Lifesciences (EW) Equity Average (2010 - 2026)

Edwards Lifesciences' Equity Average history runs 17 years deep, the most recent figure standing at $10.3 billion for Q1 2026.

• In Q1 2026, Equity Average rose 2.03% year-over-year to $10.3 billion; the TTM figure through Mar 2026 stood at $10.3 billion (up 2.03% YoY), while the FY2025 annual figure was $10.2 billion, up 21.56% from the prior year.
• Equity Average was $10.3 billion for Q1 2026 at Edwards Lifesciences, up from $10.3 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $10.4 billion in Q3 2025 to a low of $5.8 billion in Q1 2022.
• Historically, Equity Average has averaged $7.9 billion across 5 years, with a median of $7.0 billion in 2024.
• The sharpest annual moves came in 2023 and 2024: Equity Average rose 1.61% in 2023, then surged 46.32% in 2024.
• A 5-year view of Equity Average shows it stood at $6.0 billion in 2022, then gained by 11.83% to $6.7 billion in 2023, then soared by 46.32% to $9.8 billion in 2024, then increased by 4.41% to $10.3 billion in 2025, then grew by 0.6% to $10.3 billion in 2026.
• The last three Equity Average figures came in at $10.3 billion (Q1 2026), $10.3 billion (Q4 2025), and $10.4 billion (Q3 2025), per Business Quant data.